CClinicalTrials.gg
Enrolling by invitationNCT04200937Updated Sep 14, 2026

IT Matters: The Erectile Restoration Registry

An observational study in Erectile Dysfunction, sponsored by Boston Scientific Corporation. Enrolling by invitation at 25 sites in 3 countries. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Boston Scientific Corporation · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
450
Ages
18 Years and older
Sex
Male
01

Study summary

The objective of the It MATTERS registry is to collect Real-World Data (RWD) to monitor the safe and effective use of commercially available Boston Scientific Corporation (BSC) penile prostheses

Read the detailed description

IT MATTERS is a prospective, multicenter, observational registry that is part of planned, active post market clinical follow-up (PMCF) activity associated with each device.

The study will include adult males who undergo penile prothesis implantation with a market approved BSC device to treat erectile dysfunction.

02

Conditions studied

  • Erectile Dysfunction

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adult males who meet the indications for surgical correction of erectile dysfunction will be enrolled.

Inclusion criteria

  1. ≥ 18 years of age.
  2. Males who are determined to be suitable candidates and scheduled to undergo surgical implantation of a market approved BSC penile prothesis by their physician.
  3. Willing and able to complete the informed consent process.
  4. Willing and able to comply with the follow-up requirements.

Exclusion criteria

Exclusion Criteria:

  1. Males who are deemed by their physician as not suitable candidates for a penile prosthesis.
  2. In the opinion of the investigator, it is not in best interest of the patient or the study for the patient to participate.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
450 participants (estimated)
Patient registry
No

Groups and cohorts

  • BSC Penile Prothesis Recipients

    Men for whom BSC Penile Prothesis is recommended.

    Device: Tactra Malleable · Device: Spectra™ Concealable Penile Prothesis · Device: AMS Ambicor™ Inflatable Penile Prosthesis · Device: AMS 700™ Inflatable Penile Prosthesis w/Momentary Squeeze (MS) Pump · Device: AMS 700™ Inflatable Penile Prosthesis w/Tenacio™ Pump

Interventions

  • DeviceTactra Malleable

    The Tactra™ Penile Prosthesis is a sterile, single-use implant that is intended for use in the treatment of chronic, organic, erectile dysfunction (impotence) in adult males who are suitable candidates for implantation procedure.

  • DeviceSpectra™ Concealable Penile Prothesis

    The Spectra Penile Prothesis is a sterile, non-pyrogenic, single-use implant that is intended for use in the treatment of chronic, organic, erectile dysfunction (impotence) in men who are determined to be suitable candidates for implantation surgery.

  • DeviceAMS Ambicor™ Inflatable Penile Prosthesis

    The AMS Ambicor inflatable penile prothesis intended for use in the treatment of chronic, organic, male erectile dysfunction (impotence) in adult men who are determined to be suitable candidates for implantation surgery.

  • DeviceAMS 700™ Inflatable Penile Prosthesis w/Momentary Squeeze (MS) Pump

    The AMS 700 Inflatable Penile Prosthesis is intended for use in the treatment of chronic, organic, male erectile dysfunction (impotence).

  • DeviceAMS 700™ Inflatable Penile Prosthesis w/Tenacio™ Pump

    The AMS 700 Inflatable Penile Prosthesis is intended for use in the treatment of chronic, organic, male erectile dysfunction (impotence).

05

What researchers measure

Primary outcomes

  1. Change from baseline to six months in the Erectile Function domain ofthe International Index of Erectile Function (IIEF-EF) questionnaire for Tactra

    The International Index of Erectile Function (IIEF) is a validated, widely used, multidimensional self-report instrument for the evaluation of erectile function. It consists of 15 items that assess sexual function in five domains: erectile function (Q1, 2, 3, 4, 5,15), orgasmic function (Q9,10), sexual desire (Q11,12), intercourse satisfaction (Q 6,7,8) and overall satisfaction (Q 13,14). A score of 0-5 is awarded to each of the 15 questions. The IIEF-15 total score is the sum of the ordinal responses to the 5 domains. The erectile function (EF) domain is the most sensitive domain of the IIEF. IIEF-EF score ranges from 1 to 30 and is derived by scoring 0 (poorest function) to 5 (best function) on each of six questions function (Q1, 2, 3, 4, 5, 15). There are five categories of erectile function based on EF domain score: severe (1-10), moderate (11-16), mild to moderate (17-21), mild (22-25) and no ED (26-30).

    Time frame: Baseline to 6 months

Secondary outcomes

  1. Change in depressive symptoms and overall sexual function at Post-Surgery, 6 months, and 12 months post device implantation compared to baseline, as measured by the PHQ-9 Depression Questionnaire and the IIEF: Total Score.

    The Patient Health Questionnaire (PHQ) is a diagnostic tool for mental health disorders used by health care professionals. The PHQ contains: mood anxiety, alcohol, eating, and somatoform modules. The PHQ-9, is a validated tool specific to depression, scoring each of the 9 DSM-IV criteria. Scored from 0-27, the PHQ-9 is separated into five different diagnoses: minimal depression (0-4), mild depression (5-9), moderate depression (10-14), moderately severe depression (15-19), and severe depression (20-27).

    Time frame: Post-Surgery, 6 months, and 12 months

  2. Change in quality of life at 6 months, and 12 months post device implantation compared to baseline as measured by the WPAI:GH Questionnaire.

    The WPAI:GH (Work Productivity and Activity Impairment Questionnaire: General Health) is a validated tool that asks a series of questions about the effect of subject health problems, both physical and emotional, on their ability to work and perform regular activities. The WPAI:GH outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes, as following 6 questions: 1 = currently employed, 2 = hours missed due to health problems, 3 = hours missed other reasons, 4 = hours actually worked, 5 = degree health affected productivity while working, 6 = degree health affected regular activities. Scores are then multiplied by 100 to be expressed in percentages.

    Time frame: 6 months, and 12 months

  3. Change in erectile function at post-surgery, and 12 months post device implantation compared to baseline, as measured by the International Index of Erectile Function Domain (IIEF).

    The International Index of Erectile Function (IIEF) is a validated, widely used, multidimensional self-report instrument for the evaluation of erectile function. It consists of 15 items that assess sexual function in five domains: erectile function (Q1, 2, 3, 4, 5,15), orgasmic function (Q9,10), sexual desire (Q11,12), intercourse satisfaction (Q 6,7,8) and overall satisfaction (Q 13,14). A score of 0-5 is awarded to each of the 15 questions. The IIEF-15 total score is the sum of the ordinal responses to the 5 domains. The erectile function (EF) domain is the most sensitive domain of the IIEF. IIEF-EF score ranges from 1 to 30 and is derived by scoring 0 (poorest function) to 5 (best function) on each of six questions function (Q1, 2, 3, 4, 5, 15). There are five categories of erectile function based on EF domain score: severe (1-10), moderate (11-16), mild to moderate (17-21), mild (22-25) and no ED (26-30).

    Time frame: Post-Surgery, and 12 months

Other outcomes

  1. Device satisfaction at post-surgery, 6 months, and 12 months a measured by the Likert scale.

    The Likert scale has the options of Very Satisfied, Dissatisfied, Neither Satisfied nor Dissatisfied, Satisfied and Very Satisfied. Responses will be evaluated categorically.

    Time frame: Post-surgery, 6 months, and 12 months

  2. Assess for outcomes and adverse events on AMS Tools at Post Procedure.

    AMS tools will be assess by a physician survey as part of the post-procedure case report form.

    Time frame: Collected only at Post-Procedure

06

Study locations

25 sites
  • USC Medical Center
    Los Angeles, California 90033, United States
  • Ronald Reagan UCLA Medical Center
    Los Angeles, California 90095, United States
  • Tower Urology-Research Facility
    Los Angeles, California 99048, United States
  • University of Miami Hospital
    Miami, Florida 33136, United States
  • USF Health South Tampa Center for Advanced Healthcare
    Tampa, Florida 33606, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • SIU School of Medicine
    Springfield, Illinois 62702, United States
  • Indiana University Medical Center
    Indianapolis, Indiana 46202, United States
  • Willis-Knighton Medical Center
    Bossier City, Louisiana 71111, United States
  • Washington University in St. Louis
    St Louis, Missouri 63110, United States
  • Duke University Medical Center
    Raleigh, North Carolina 27609, United States
  • W.G. Hefner VA Medical Center
    Salisbury, North Carolina 28144, United States
  • Wake Forest University
    Winston-Salem, North Carolina 27103, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Ohio State University Wexner Medical Center
    Columbus, Ohio 43212, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Peking University First Hospital
    Beijing, 100034, China
  • Shanghai General Hospital
    Shanghai, 200080, China
  • Shanghai Jiaotong University School of Medicine Renji Hospital
    Shanghai, 200127, China
  • Johns Hopkins Aramco Healthcare
    Dhahran, 34465, Saudi Arabia
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT04200937
Lead sponsor
Boston Scientific Corporation
Responsible party
Sponsor
First posted
Dec 16, 2019
Start date
Aug 5, 2021
Primary completion
Jan 2031 (estimated)
Completion
Dec 2031 (estimated)
Last update
Sep 14, 2026

Study contacts

Mohit Khera, MD
principal investigator · Baylor College of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion